Prothena Plc Stock Performance
| PRTA Stock | USD 14.15 0.40 2.75% |
The company holds a Beta of 3.03, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Prothena Plc will likely underperform. At this point, Prothena plc has a negative expected return of -0.49%. Please make sure to check Prothena Plc's skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Prothena plc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Prothena plc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 1.25 | Five Day Return 3.05 | Year To Date Return (62.25) | Ten Year Return (21.31) | All Time Return 102.08 |
1 | Crude Oil Moves Higher Prime Medicine Shares Spike Higher | 09/30/2024 |
2 | Prothena Rating Reiterated by Cantor Fitzgerald | 10/02/2024 |
3 | State Street Corps Strategic Reduction in Prothena Corp PLC Holdings | 10/18/2024 |
4 | Acquisition by Walker Karin L of 54000 shares of Prothena Plc at 30.3 subject to Rule 16b-3 | 10/23/2024 |
5 | Disposition of 66 shares by Walker Karin L of Prothena Plc at 68.9572 subject to Rule 16b-3 | 10/25/2024 |
6 | Prothena Upgraded to Buy What Does It Mean for the Stock | 10/29/2024 |
7 | Wellington Management Group LLPs Strategic Acquisition in Prothena Corp PLC | 11/07/2024 |
8 | Prothena Set to Announce Earnings on Tuesday | 11/11/2024 |
9 | Prothena earnings beat by 0.08, revenue fell short of estimates | 11/12/2024 |
10 | Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe | 11/15/2024 |
11 | Prothena Co. plc Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat | 12/09/2024 |
| Begin Period Cash Flow | 712.6 M |
Prothena |
Prothena Plc Relative Risk vs. Return Landscape
If you would invest 2,072 in Prothena plc on September 12, 2024 and sell it today you would lose (657.00) from holding Prothena plc or give up 31.71% of portfolio value over 90 days. Prothena plc is currently does not generate positive expected returns and assumes 4.5689% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Prothena, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Prothena Plc Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prothena Plc's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Prothena plc, and traders can use it to determine the average amount a Prothena Plc's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.107
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PRTA |
Estimated Market Risk
| 4.57 actual daily | 40 60% of assets are more volatile |
Expected Return
| -0.49 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Prothena Plc is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Prothena Plc by adding Prothena Plc to a well-diversified portfolio.
Prothena Plc Fundamentals Growth
Prothena Stock prices reflect investors' perceptions of the future prospects and financial health of Prothena Plc, and Prothena Plc fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Prothena Stock performance.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.99) % | ||||
| Operating Margin | (68.57) % | ||||
| Current Valuation | 265.46 M | ||||
| Shares Outstanding | 53.81 M | ||||
| Price To Earning | 37.12 X | ||||
| Price To Book | 1.45 X | ||||
| Price To Sales | 5.87 X | ||||
| Revenue | 91.37 M | ||||
| Gross Profit | (81.66 M) | ||||
| EBITDA | (190.11 M) | ||||
| Net Income | (147.03 M) | ||||
| Cash And Equivalents | 508.8 M | ||||
| Cash Per Share | 10.84 X | ||||
| Total Debt | 11.84 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 13.00 X | ||||
| Book Value Per Share | 9.93 X | ||||
| Cash Flow From Operations | (133.91 M) | ||||
| Earnings Per Share | (2.46) X | ||||
| Market Capitalization | 782.92 M | ||||
| Total Asset | 696.38 M | ||||
| Retained Earnings | (980.03 M) | ||||
| Working Capital | 582.39 M | ||||
| Current Asset | 377.4 M | ||||
| Current Liabilities | 22.22 M | ||||
About Prothena Plc Performance
By analyzing Prothena Plc's fundamental ratios, stakeholders can gain valuable insights into Prothena Plc's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Prothena Plc has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Prothena Plc has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (3.02) | (3.17) | |
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.30) | (0.28) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.26) | (0.25) |
Things to note about Prothena plc performance evaluation
Checking the ongoing alerts about Prothena Plc for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Prothena plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Prothena plc generated a negative expected return over the last 90 days | |
| Prothena plc has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 91.37 M. Net Loss for the year was (147.03 M) with loss before overhead, payroll, taxes, and interest of (81.66 M). | |
| Prothena plc currently holds about 508.8 M in cash with (133.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.84. | |
| Prothena plc has a poor financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Prothena Co. plc Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat |
- Analyzing Prothena Plc's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Prothena Plc's stock is overvalued or undervalued compared to its peers.
- Examining Prothena Plc's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Prothena Plc's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Prothena Plc's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Prothena Plc's stock. These opinions can provide insight into Prothena Plc's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Prothena Stock analysis
When running Prothena Plc's price analysis, check to measure Prothena Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prothena Plc is operating at the current time. Most of Prothena Plc's value examination focuses on studying past and present price action to predict the probability of Prothena Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prothena Plc's price. Additionally, you may evaluate how the addition of Prothena Plc to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |